Computer-Guided statin dosing shows promise for liver patients

NCT ID NCT07459972

Completed Knowledge-focused Sponsor: Kafrelsheikh University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a computer program could help doctors choose the right dose of simvastatin for people with cirrhosis and high blood pressure in the liver. Twenty-two patients received either 5 mg or 15 mg of simvastatin daily for three months. Researchers measured changes in liver blood flow and checked for side effects to see if the computer-guided dosing was safe and effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Simvastatin
What this could lead to: If successful, this approach could help doctors personalize statin doses for people with liver disease, potentially reducing complications from high blood pressure in the liver.
What could go wrong: This was a small pilot study with only 22 participants, so results may not apply to everyone. The study focused on short-term safety and blood flow changes, not long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIVER CIRRHOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver portal hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LIVER CIRRHOSIS PORTAL HYPERTENSION RELATED TO CIRRHOSIS

Contacts and locations

Locations

Kafrelsheikh University

Cairo, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.